Trial Profile

A Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food-effect of ACCG-2671

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 21 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Sep 2026 According to a Structure Therapeutics media release, based on the encouraging SAD findings, the company has initiated the multiple ascending dose (MAD) portion of the Phase 1/2a clinical trial of ACCG-2671, with the first participants dosed. Topline results are expected in the first half of 2027.
08 Sep 2026 Results (n=31) presented from SAD portion Structure Therapeutics media release
08 Sep 2026 According to Structure Therapeutics media release, first participants dosed with ACCG-2671 in the 12-week MAD portion of the phase 1/2a clinical trial and topline data expected in 1H 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com